Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:301393's Forward Dividend Yield % is ranked worse than 68.91% of 505
companies
in the Drug Manufacturers industry
Industry Median: 2.02
vs SZSE:301393: 1.09
Suzhou Highfine Biotech Co (SZSE:301393) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Suzhou Highfine Biotech Co Forward Dividend Yield % Related Terms
SZSE:301393 vs ZTS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Suzhou Highfine Biotech Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Highfine Biotech Co Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suzhou Highfine Biotech Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Suzhou Highfine Biotech Co's Forward Dividend Yield % falls into.
Suzhou Highfine Biotech Co Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Suzhou Highfine Biotech Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CNY 0.270000
2026-05-21
2026-05-20
2026-05-21
Cash Dividend
semi-annually
CNY:CNY 1.000000
CNY 0.135000
2025-11-11
2025-11-10
2025-11-11
Cash Dividend
semi-annually
CNY:CNY 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 1.09% mean?
Suzhou Highfine Biotech Co (SZSE:301393) has a Forward Dividend Yield % of 1.09% as of Aug. 24, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Suzhou Highfine Biotech Co and its competitors. According to the industry distribution chart, Suzhou Highfine Biotech Co ranks #348 out of 505 companies in the Drug Manufacturers industry, placing it in the top 68.9%.
Is Suzhou Highfine Biotech Co's Forward Dividend Yield % too high?
Suzhou Highfine Biotech Co's current Forward Dividend Yield % is 1.09%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.02. Suzhou Highfine Biotech Co's value of 1.09% is 46% below this industry median. Based on the distribution chart, Suzhou Highfine Biotech Co ranks #348 out of 505 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Suzhou Highfine Biotech Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Highfine Biotech Co's Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suzhou Highfine Biotech Co ranks #348 out of 505 companies for Forward Dividend Yield %. This places Suzhou Highfine Biotech Co in the lower half of its industry. The industry median Forward Dividend Yield % is 2.02. Suzhou Highfine Biotech Co's value of 1.09% is 46% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.02, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Highfine Biotech Co's current Forward Dividend Yield % of 1.09% is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Suzhou Highfine Biotech Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Highfine Biotech Co's current Forward Dividend Yield % is 1.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Highfine Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co (SZSE:301393) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥71.95, compared to a current price of ¥61.32 — trading 14.8% below its estimated fair value. The current Forward Dividend Yield % is 1.09% and 46% below the Drug Manufacturers industry median of 2.02. Suzhou Highfine Biotech Co's overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Suzhou Highfine Biotech Co (SZSE:301393), the current Forward Dividend Yield % is 1.09% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Highfine Biotech Co (SZSE:301393) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co stock appears to be undervalued.
The current stock price of ¥61.32 is trading 14.8% below its estimated GF Value™ of ¥71.95.
GuruFocus considers Suzhou Highfine Biotech Co to be Modestly Undervalued.
Key valuation signals for SZSE:301393:
Forward Dividend Yield %: 1.09%
GF Value™: ¥71.95 vs. price of ¥61.32 (14.8% below fair value)
Industry Position: 46% below the Drug Manufacturers median (#348 of 505)
No single metric tells the full story. See the SZSE:301393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.
91GF Score
Get the complete analysis for SZSE:301393
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301393 has been successfully added to your 
